
Novavax COVID-19 vaccine 90.4% effective in clinical trial, company says
Fox News
Novavax announced on Monday that its COVID-19 vaccine was found to be over 90% effective overall, and offered 100% protection against moderate and severe disease in a Phase 3 clinical trial.
The Phase 3 PREVENT-19 trial had enrolled nearly 30,000 participants ages 18 and older in the U.S. and Mexico. Data reflected 63 COVID-19 cases reported among the placebo group and 14 in the vaccine group. All cases identified in the vaccine group were classified as mild, while 10 cases in the placebo group were moderate and four were severe. The vaccine also demonstrated over 93% efficacy against variants of concern and variants of interest that were detected through sequencing of confirmed cases in the trial.More Related News